# MEG Study of Acute STX209 Effects in ASD

> **NCT02278328** · EARLY_PHASE1 · COMPLETED · sponsor: **Timothy Roberts** · enrollment: 25 (actual)

## Conditions studied

- Autism Disorder

## Interventions

- **DRUG:** STX209 (15mg)
- **DRUG:** placebo
- **DRUG:** STX209 (30mg)

## Key facts

- **NCT ID:** NCT02278328
- **Lead sponsor:** Timothy Roberts
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2018-07-30
- **Final completion:** 2019-09-27
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-10-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02278328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02278328, "MEG Study of Acute STX209 Effects in ASD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02278328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*